VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know

Key Takeaways The phase II study showed VTX3232 was safe and well-tolerated as monotherapy and with Wegovy.VTYX reported major hsCRP and IL-6 reductions plus improvements in key inflammatory biomarkers.Combination therapy with Wegovy cut inflammation further but did not enhance weight-loss outcomes.Shares of Ventyx Biosciences (VTYX) have skyrocketed 156% in the past month. The massive surge in the stock price was primarily driven by the success of the company’s mid-stage study evaluating its investigationa ...